- Home
- TAK vs PSX Comparison
TAK vs PSX Comparison
Compare TAK & PSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- PSX
- Stock Information
- Founded
- TAK 1781
- PSX 1875
- Country
- TAK Japan
- PSX United States
- Employees
- TAK N/A
- PSX N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- PSX Integrated oil Companies
- Sector
- TAK Health Care
- PSX Energy
- Exchange
- TAK Nasdaq
- PSX Nasdaq
- Market Cap
- TAK 44.4B
- PSX 50.5B
- IPO Year
- TAK N/A
- PSX 2012
- Fundamental
- Price
- TAK $15.03
- PSX $113.40
- Analyst Decision
- TAK
- PSX Buy
- Analyst Count
- TAK 0
- PSX 14
- Target Price
- TAK N/A
- PSX $139.77
- AVG Volume (30 Days)
- TAK 2.2M
- PSX 3.5M
- Earning Date
- TAK 05-08-2025
- PSX 04-25-2025
- Dividend Yield
- TAK 3.92%
- PSX 4.23%
- EPS Growth
- TAK N/A
- PSX N/A
- EPS
- TAK 0.45
- PSX 4.42
- Revenue
- TAK $30,595,075,281.00
- PSX $137,772,000,000.00
- Revenue This Year
- TAK $1.01
- PSX N/A
- Revenue Next Year
- TAK $1.04
- PSX $0.84
- P/E Ratio
- TAK $64.83
- PSX $25.65
- Revenue Growth
- TAK 7.45
- PSX N/A
- 52 Week Low
- TAK $12.58
- PSX $91.01
- 52 Week High
- TAK $15.43
- PSX $150.12
- Technical
- Relative Strength Index (RSI)
- TAK 60.23
- PSX 49.75
- Support Level
- TAK $14.51
- PSX $112.29
- Resistance Level
- TAK $14.75
- PSX $115.57
- Average True Range (ATR)
- TAK 0.21
- PSX 3.01
- MACD
- TAK 0.09
- PSX -0.68
- Stochastic Oscillator
- TAK 99.66
- PSX 21.55
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About PSX Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 1.8 million barrels per day, or mmb/d. In 2023, the Rodeo, California, facility ceased operations and be converted to produce renewable diesel. The midstream segment comprises extensive transportation and NGL processing assets and includes DCP Midstream, which holds 600 mbd of NGL fractionation and 22,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.